Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Total Current Liabilities of $129.7 million for Q1 2026, down 12.19% on a QoQ basis from $147.7 million in Q4 2025, and down 8.65% year-over-year from $142.0 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $129.7 million for Q1 2026.
- Quarterly Total Current Liabilities fell 8.65% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.7 million (down 8.65% YoY) and the FY2025 annual result came in at $147.7 million, down 21.21% from the prior year.
- Total Current Liabilities was $129.7 million for Q1 2026 at Recursion Pharmaceuticals, down from $147.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $187.5 million in Q4 2024 and bottomed at $73.9 million in Q1 2024.
- A 5-year average of $114.9 million and a median of $100.3 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 227.19% — and 2024, when it decreased 24.46%.
- Recursion Pharmaceuticals' Total Current Liabilities stood at $100.3 million in 2022, then retreated by 7.08% to $93.2 million in 2023, then surged by 101.21% to $187.5 million in 2024, then decreased by 21.21% to $147.7 million in 2025, then retreated by 12.19% to $129.7 million in 2026.
- Business Quant data shows RXRX's Total Current Liabilities at $129.7 million in Q1 2026, $147.7 million in Q4 2025, and $155.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | 129.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 129.70 Mn |
| Dec 31, 2025 | 147.71 Mn |
| Sep 30, 2025 | 155.10 Mn |
| Jun 30, 2025 | 164.03 Mn |
| Mar 31, 2025 | 141.98 Mn |
| Dec 31, 2024 | 187.47 Mn |
| Sep 30, 2024 | 108.89 Mn |
| Jun 30, 2024 | 86.08 Mn |
| Mar 31, 2024 | 73.92 Mn |
| Dec 31, 2023 | 93.17 Mn |
| Sep 30, 2023 | 94.12 Mn |
| Jun 30, 2023 | 113.96 Mn |
| Mar 31, 2023 | 92.15 Mn |
| Dec 31, 2022 | 100.27 Mn |
| Sep 30, 2022 | 83.04 Mn |
| Jun 30, 2022 | 96.65 Mn |
| Mar 31, 2022 | 85.71 Mn |
| Dec 31, 2021 | 46.66 Mn |
| Sep 30, 2021 | 42.94 Mn |
| Jun 30, 2021 | 29.54 Mn |